Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Regeneron Pharmaceuticals    REGN

REGENERON PHARMACEUTICALS

(REGN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Regeneron Pharmaceuticals : U.S. to begin distributing Regeneron's COVID-19 antibody therapy Tuesday

11/23/2020 | 03:25pm EST

Nov 23 (Reuters) - The U.S. government will start distributing Regeneron Pharmaceuticals Inc's newly authorized COVID-19 antibody combination on Tuesday, beginning with over 30,000 treatment courses, a health official said on Monday.

U.S. officials on a call with reporters said doses will be allocated based on which states have the highest numbers of confirmed cases and hospitalizations, both of which are currently soaring nationwide.

The U.S. Food and Drug Administration on Saturday issued emergency use authorization for the treatment called REGN-COV2, which combines two monoclonal antibodies, to be used for mild-to-moderate COVID-19 in adults and children who are at high risk of progressing to severe COVID-19.

Regeneron has said it expects to have enough REGEN-COV2 for about 80,000 patients by the end of this month. It expects to have enough doses to treat about 200,000 patients by the first week of January, rising to some 300,000 patients in total by the end of January.

The antibody cocktail was among the treatments given to U.S. President Trump during his bout with COVID-19 last month. He declared it a virtual "cure" for COVID-19 at the time.

The treatment belongs to a class of biotech drugs known as monoclonal antibodies, which are manufactured copies of antibodies created by the human body to fight infections.

U.S. regulators earlier this month authorized another antibody treatment for COVID-19 from Eli Lilly and Co. Officials on Monday said the department of Health and Human Services has already helped distribute 120,000 doses of Lilly's antibody to patients around the country.

More than 250,000 Americans have also been treated for their COVID-19 with antibody-rich convalescent plasma from recovered patients, officials said. Some health experts have argued that there is not enough data to show that convalescent plasma is an effective treatment. (Reporting by Manojna Maddipatla in Bengaluru and Carl O'Donnell in New York; Editing by Chizu Nomiyama and Bill Berkrot)


© Reuters 2020
Stocks mentioned in the article
ChangeLast1st jan.
ELI LILLY AND COMPANY 1.87% 206.14 Delayed Quote.22.09%
REGENERON PHARMACEUTICALS 0.43% 537.78 Delayed Quote.11.32%
All news about REGENERON PHARMACEUTICALS
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21REGENERON PHARMACEUTICALS : Forty of the Nation's Most Talented Young Scientists..
PR
01/21Lilly Antibody Drug Prevents Covid-19 in Nursing Homes, Study Finds
DJ
01/19REGENERON PHARMACEUTICALS : to Report Fourth Quarter and Full Year 2020 Financia..
PR
01/19REGENERON PHARMACEUTICALS : Morgan Stanley Adjusts Regeneron Pharmaceuticals PT ..
MT
01/15REGENERON PHARMACEUTICALS, INC. : Entry into a Material Definitive Agreement (fo..
AQ
01/13S&P closes higher with defensive sectors leading gains
RE
01/13Wall St gains steadily while impeachment hearings get underway
RE
01/13SECTOR UPDATE : Health Care Stocks Trading Lower Premarket Wednesday
MT
01/13REGENERON PHARMACEUTICALS : Benchmark Upgrades Regeneron Pharmaceuticals to Buy ..
MT
More news
Financials (USD)
Sales 2020 8 519 M - -
Net income 2020 3 191 M - -
Net cash 2020 5 478 M - -
P/E ratio 2020 19,1x
Yield 2020 -
Capitalization 56 760 M 56 760 M -
EV / Sales 2020 6,02x
EV / Sales 2021 4,43x
Nbr of Employees 8 314
Free-Float 83,1%
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 654,96 $
Last Close Price 537,78 $
Spread / Highest target 47,5%
Spread / Average Target 21,8%
Spread / Lowest Target -7,03%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
P. Roy Vagelos Chairman
Patrice Gilooly Senior VP-Quality Assurance & Operations
Robert E. Landry Chief Financial Officer & Executive VP-Finance
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS11.32%56 760
GILEAD SCIENCES, INC.14.90%83 911
WUXI APPTEC CO., LTD.30.64%66 044
VERTEX PHARMACEUTICALS0.53%61 782
BEIGENE, LTD.44.94%34 148
GENMAB A/S7.31%28 292